Skip to content
Bored Studies
RecruitingPhase 2

Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease

Regeneron Pharmaceuticals · NCT07271186

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–80 · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 2
Target enrollment
195
US sites recruiting
56
Study start
January 9, 2026
Record last updated
October 8, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

This study is researching an experimental drug called ALN-ANG3 (called "study drug"). The study is focused on participants who have diabetic kidney disease.

The aim of the study is to see how safe and effective the study drugs are.

The study is looking at several other research questions, including:

  • What side effects may happen from taking the study drug
  • How much study drug is in the blood at different times

Being studied: ALN-ANG3; Evinacumab; Placebo

Conditions: Diabetic Kidney Disease (DKD)

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Key Inclusion Criteria

  • Medical history of type 2 diabetes and receiving medical therapy or lifestyle interventions for glucose management
  • Hemoglobin A1C (HbA1c) of 6.5 to 10% at screening
  • eGFR 30 to 90 mL/min/1.73 m\^2 using 2021 Chronic Kidney Disease-Epidemiology Collaboration-Estimated Glomerular Filtration Rate using Creatinine and Cystatin C (CKD-EPI eGFRcr-cys) equation at screening
  • Albuminuria: Urine Albumin to Creatinine Ratio (UACR) of 500 to 5000 mg/g at screening

Key Exclusion Criteria

  • Known medical history or clinical evidence indicative of non-diabetic renal disease
  • Renal disease that required treatment with systemic immunosuppressive therapy (prior or current), or a history of end-stage kidney disease requiring treatment with chronic dialysis or kidney transplantation
  • Medically unstable as assessed by the investigator or hospitalization (ie, >24 hours) within 30 days of the screening visit

NOTE: Other Protocol-Defined Inclusion/Exclusion Criteria Apply

Recruiting US locations

Study contacts (from the official record)

  • Clinical Trials Administrator · 844-734-6643 · clinicaltrials@regeneron.com
All diabetes studies in Alabama →
Study to Assess the Effects of ALN-ANG3 in Adult Participants With… (NCT07271186) | Bored Studies